BRPI0402382A - Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais - Google Patents

Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais

Info

Publication number
BRPI0402382A
BRPI0402382A BR0402382-0A BRPI0402382A BRPI0402382A BR PI0402382 A BRPI0402382 A BR PI0402382A BR PI0402382 A BRPI0402382 A BR PI0402382A BR PI0402382 A BRPI0402382 A BR PI0402382A
Authority
BR
Brazil
Prior art keywords
rifaximin
production
forms
processes
polymorphic forms
Prior art date
Application number
BR0402382-0A
Other languages
English (en)
Inventor
Giuseppe C Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Denis Severini
Paolo Righi
Goffredo Rosini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0402382(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of BRPI0402382A publication Critical patent/BRPI0402382A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMAS POLIMóRFICAS DE RIFAXIMINA, PROCESSOS PARA A PRODUçãO DAS MESMAS E USO DAS MESMAS EM PREPARAçõES MEDICINAIS". A presente invenção refere-se a formas polimórficas cristalinas do antibiótico rifaximina (INN) denominadas rifaximina <244> e rifaximina <225> e uma forma fracamente cristalina denominada rifaximina <sym>. Estas formas são úteis na produção de preparações medicinais para uso oral e tópico e podem ser obtidas por meio de um processo de cristalização realizado por dissolução a quente da rifaximina bruta em álcool etílico e provocando-se a cristalização do produto pela adição de água a uma temperatura predeterminada e durante um período de tempo determinado. A cristalização é seguida de secagem realizada sob condições controladas até que seja conseguido um teor de água específico no produto final.
BR0402382-0A 2003-11-07 2004-03-19 Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais BRPI0402382A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
BRPI0402382A true BRPI0402382A (pt) 2005-06-28

Family

ID=33187382

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0402382-0A BRPI0402382A (pt) 2003-11-07 2004-03-19 Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais
BRPI0407149A BRPI0407149A8 (pt) 2003-11-07 2004-11-04 formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0407149A BRPI0407149A8 (pt) 2003-11-07 2004-11-04 formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais

Country Status (38)

Country Link
US (5) US7045620B2 (pt)
EP (6) EP1676847B1 (pt)
JP (5) JP2005139161A (pt)
KR (4) KR20050043589A (pt)
CN (4) CN1613858A (pt)
AR (3) AR043547A1 (pt)
AT (3) ATE421966T1 (pt)
AU (2) AU2004200964A1 (pt)
BR (2) BRPI0402382A (pt)
CA (2) CA2460384A1 (pt)
CL (1) CL2004000498A1 (pt)
CO (1) CO5560083A1 (pt)
CY (3) CY1108017T1 (pt)
DE (4) DE602004019296D1 (pt)
DK (3) DK1676848T3 (pt)
ES (3) ES2320160T4 (pt)
HK (3) HK1092150A1 (pt)
HR (2) HRP20040265A2 (pt)
IL (2) IL160798A0 (pt)
IT (1) ITMI20032144A1 (pt)
JO (1) JO2470B1 (pt)
MA (1) MA27069A1 (pt)
MD (1) MD3653G8 (pt)
ME (1) ME00424B (pt)
MX (2) MXPA04002353A (pt)
NO (1) NO334950B1 (pt)
NZ (1) NZ531622A (pt)
PL (3) PL1676847T3 (pt)
PT (3) PT1676848E (pt)
RS (4) RS20060168A (pt)
RU (1) RU2270200C2 (pt)
SI (3) SI1676847T1 (pt)
TN (2) TNSN04044A1 (pt)
TW (1) TWI285107B (pt)
UA (1) UA86384C2 (pt)
WO (1) WO2005044823A2 (pt)
YU (1) YU24804A (pt)
ZA (1) ZA200401948B (pt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
SI1698630T1 (sl) * 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
BRPI0714724A8 (pt) 2006-08-02 2018-04-10 Salix Pharmaceuticals Inc métodos para tratar enterite, para proteger contra a enterite, contra a lesão à mucosa do cólon e contra a inflamação colorretal induzidas pela radiação, para tratar enterite em um indivíduo ou monitorar o progresso de um indivíduo que é tratado de enterite, para selecionar um indivíduo para o tratamento de enterite, e, para tratar diarréia profilaticamente.
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
KR101667534B1 (ko) * 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
ES2389358T5 (es) * 2007-07-06 2016-01-19 Lupin Ltd. Composiciones farmacéuticas de rifaximina
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
BRPI0908864A2 (pt) * 2008-02-25 2018-09-18 Salix Pharmaceuticals Ltd formas da rifaximina e usos das mesmas
PL2252148T3 (pl) 2008-02-26 2019-09-30 Salix Pharmaceuticals, Ltd. Sposoby leczenia zespołu jelita drażliwego
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
DK2294012T3 (da) 2008-05-07 2014-10-06 Salix Pharmaceuticals Ltd Administration af et tarmrensemiddel og et antibiotika til behandlingen af tarmsygdom
PT2327407E (pt) 2008-09-26 2014-09-10 Aska Pharm Co Ltd Agentes profiláticos e/ou terapêuticos para desordens gastrointestinais funcionais
DK3628319T3 (da) * 2008-10-02 2024-03-04 Salix Pharmaceuticals Ltd Behandling af hepatisk encefalopati ved anvendelse af rifaximin
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
JP5756020B2 (ja) 2008-12-10 2015-07-29 シプラ・リミテッド リファキシミン複合体
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
CN102548408A (zh) * 2009-06-02 2012-07-04 萨利克斯药品有限公司 治疗肝性脑病的方法
BR112012005627A2 (pt) 2009-09-13 2017-02-21 Salix Pharmaceuticals Ltd "uso de rifaximina para preparação de um medicamento para tratar síndrome do intestino irritável (ibs)"
KR102456997B1 (ko) * 2009-10-27 2022-10-19 루핀 리미티드 리팍시민의 고형 분산물
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
WO2011061519A2 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
WO2011080691A1 (en) 2009-12-28 2011-07-07 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
EP2536282A4 (en) 2010-02-18 2013-07-03 Salix Pharmaceuticals Ltd METHOD FOR THE TREATMENT OF INFECTIONS
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
MX2012013945A (es) * 2010-06-03 2013-05-06 Salix Pharmaceuticals Ltd Nuevas formas de rifaximina y usos de las mismas.
CA2802874A1 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
HUE049986T2 (hu) * 2010-07-12 2020-11-30 Salix Pharmaceuticals Inc Rifaximin készítmények és ezek alkalmazásai
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
EA201391171A1 (ru) 2011-02-11 2014-11-28 Сэликс Фармасьютиклз, Лтд. Формы рифаксимина и их применение
EP2705042A1 (en) 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CA2854380A1 (en) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
CA2876737A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
MX2015011802A (es) 2013-03-15 2016-01-08 Alfa Wassermann Spa Rifaximina para usarse en el tratamiento de infecciones vaginales.
JP2016516988A (ja) 2013-03-15 2016-06-09 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． 膣感染症を診断するための方法
MX2015014307A (es) 2013-04-12 2015-12-08 Alfa Wassermann Spa Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados.
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) * 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
US9765088B2 (en) 2014-04-19 2017-09-19 Granules India Limited Process for the preparation of rifamycin derivatives
CN106795192B (zh) 2014-05-04 2020-06-16 萨利克斯药品公司 Ibs微生物群及其用途
PL3546464T3 (pl) 2014-05-12 2020-11-02 Alfasigma S.P.A. Sposób wytwarzania i zastosowanie postaci krystalicznej Tau rifaksyminy solwatowanej z DEGME
CN106999477B (zh) * 2014-06-30 2020-04-10 萨利克斯药品公司 用于重复治疗肠易激综合征(ibs)的方法
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
EP3536311B1 (en) 2016-03-24 2021-12-22 Sandoz AG Storage stable composition comprising rifaximin alpha
PL3434265T3 (pl) 2016-03-24 2021-12-13 Sandoz Ag Kompozycja farmaceutyczna zawierająca rifaksyminę alfa i delta
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
JP7027412B2 (ja) 2016-09-30 2022-03-01 サリックス ファーマスーティカルズ，インコーポレーテッド リファキシミンの固体分散体の形態
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
MX2018010065A (es) 2017-04-26 2019-02-07 Sandoz Ag Forma de dosificacion oral que comprende rifaximina en forma beta.
HUE054832T2 (hu) 2017-06-26 2021-10-28 Biofer Spa Pirido-imidazo rifamicinszármazékok baktériumellenes szerként
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
CN114401721A (zh) 2019-09-24 2022-04-26 博士医疗爱尔兰有限公司 利福昔明液体制剂
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
JP2023531268A (ja) 2020-06-26 2023-07-21 バウシュ ヘルス アイルランド リミテッド 標的化放出リファキシミン組成物
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
ES2075454T3 (es) * 1990-06-29 1995-10-01 Lepetit Spa Forma cristalina pura de rifapentina.
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
US6906087B2 (en) * 2000-10-31 2005-06-14 Ciba Specialty Chemicals Corpation Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
KR101667534B1 (ko) 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008005A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
ES2389358T5 (es) 2007-07-06 2016-01-19 Lupin Ltd. Composiciones farmacéuticas de rifaximina
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (en) 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
BRPI0908864A2 (pt) 2008-02-25 2018-09-18 Salix Pharmaceuticals Ltd formas da rifaximina e usos das mesmas

Also Published As

Publication number Publication date
PL1676847T3 (pl) 2009-07-31
PL1557421T3 (pl) 2007-08-31
ATE421966T1 (de) 2009-02-15
US20050101598A1 (en) 2005-05-12
KR100883216B1 (ko) 2009-02-13
BRPI0407149A8 (pt) 2019-01-15
ITMI20032144A1 (it) 2005-05-08
IL174271A0 (en) 2006-08-01
EP2210893A1 (en) 2010-07-28
KR20060110737A (ko) 2006-10-25
SI1676847T1 (sl) 2009-06-30
KR100855084B1 (ko) 2008-08-29
HRP20060093A2 (en) 2006-05-31
RS20150291A1 (en) 2015-10-30
TWI285107B (en) 2007-08-11
IL160798A0 (en) 2004-08-31
HK1092151A1 (en) 2007-02-02
JP2011046738A (ja) 2011-03-10
CA2460384A1 (en) 2005-05-07
JP5199576B2 (ja) 2013-05-15
US7045620B2 (en) 2006-05-16
AU2004287601A1 (en) 2005-05-19
CN101260115B (zh) 2011-11-23
IL174271A (en) 2010-12-30
CA2538546C (en) 2011-04-19
WO2005044823A2 (en) 2005-05-19
KR20050043589A (ko) 2005-05-11
RS20150292A1 (en) 2015-10-30
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
CN101260114A (zh) 2008-09-10
YU24804A (sh) 2006-08-17
ES2320160T4 (es) 2011-03-09
CN101260114B (zh) 2012-11-28
HK1092150A1 (en) 2007-02-02
RS20060168A (en) 2008-09-29
EP1682556A2 (en) 2006-07-26
ATE361927T1 (de) 2007-06-15
CN101260115A (zh) 2008-09-10
JP2014177500A (ja) 2014-09-25
UA86384C2 (uk) 2009-04-27
CY1108909T1 (el) 2014-07-02
MD3653F2 (en) 2008-07-31
RS54568B1 (en) 2016-06-30
AR081991A2 (es) 2012-10-31
BRPI0407149A (pt) 2006-02-07
NO20061110L (no) 2006-04-19
EP1676848A1 (en) 2006-07-05
ATE421965T1 (de) 2009-02-15
RU2004108953A (ru) 2005-10-27
US7915275B2 (en) 2011-03-29
NO334950B1 (no) 2014-08-04
MD3653G8 (ro) 2016-08-31
PT1557421E (pt) 2007-07-31
NZ531622A (en) 2004-10-29
AU2004200964A1 (en) 2005-05-26
ES2244364T3 (es) 2007-12-01
RS54569B1 (en) 2016-06-30
AR081992A2 (es) 2012-10-31
CN1886408B (zh) 2010-06-09
JP2005139161A (ja) 2005-06-02
ME00424B (me) 2011-10-10
DE602004019296D1 (de) 2009-03-19
DE602004006367T2 (de) 2007-09-06
CO5560083A1 (es) 2005-09-30
SI1557421T1 (sl) 2007-08-31
CL2004000498A1 (es) 2005-03-11
TNSN06069A1 (en) 2007-10-03
CY1108964T1 (el) 2014-07-02
KR100867751B1 (ko) 2008-11-10
JO2470B1 (en) 2009-01-20
SI1676848T1 (sl) 2009-06-30
ES2320161T3 (es) 2009-05-19
MXPA06002644A (es) 2006-06-06
MD20060080A (en) 2006-11-30
DK1676847T3 (da) 2009-05-11
US20080132530A1 (en) 2008-06-05
MA27069A1 (fr) 2004-12-20
US8404704B2 (en) 2013-03-26
PT1676848E (pt) 2009-04-09
DK1557421T3 (da) 2007-09-17
ZA200401948B (en) 2004-04-29
US20110160449A1 (en) 2011-06-30
KR20070113326A (ko) 2007-11-28
CN1613858A (zh) 2005-05-11
DE602004006367C5 (de) 2019-04-04
TNSN04044A1 (en) 2006-06-01
HK1073657A1 (en) 2005-10-14
AR043547A1 (es) 2005-08-03
CY1108017T1 (el) 2013-09-04
JP2007509904A (ja) 2007-04-19
HRP20060093B1 (hr) 2015-12-18
US20050272754A1 (en) 2005-12-08
EP1676847A1 (en) 2006-07-05
EP1557421B1 (en) 2007-05-09
EP2208730A1 (en) 2010-07-21
EP1557421A1 (en) 2005-07-27
ES2244364T1 (es) 2005-12-16
RS54571B1 (en) 2016-06-30
AU2004287601B2 (en) 2009-02-26
KR20070113327A (ko) 2007-11-28
RU2270200C2 (ru) 2006-02-20
EP1676847B1 (en) 2009-01-28
DE602004006367D1 (de) 2007-06-21
DE602004019298D1 (de) 2009-03-19
US8173801B2 (en) 2012-05-08
MXPA04002353A (es) 2005-05-11
EP1676848B1 (en) 2009-01-28
JP2011057698A (ja) 2011-03-24
CN1886408A (zh) 2006-12-27
PL1676848T3 (pl) 2009-07-31
TW200515913A (en) 2005-05-16
WO2005044823A3 (en) 2005-10-27
DK1676848T3 (da) 2009-05-11
CA2538546A1 (en) 2005-05-19
DE04005541T1 (de) 2005-12-29
AU2004287601B8 (en) 2009-03-05
JP5635376B2 (ja) 2014-12-03
PT1676847E (pt) 2009-04-09
US20120059023A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
BRPI0402382A (pt) Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais
BRPI0608073A2 (pt) formas polimorfas de rifaximina, processos para sua produção e uso das mesmas em composições medicinais
ES2229804T3 (es) Etannolato de azitromicina, procedimiento para su fabricacion y composiciones farmaceuticas que lo contienen.
ES2505615T3 (es) Proceso para fabricar zeolita de tipo MWW de titanio
BRPI0515170A (pt) processos para a produção de (s) -2- (1, 6, 7, 8- tetraidro-2h-indeno [5, 4 -b] furan -8- il) etilamina ou um sal do mesmo e para a produção de cristais de (s) -n- [2- (1, 6, 7, 8 - tetraidro -2h- indeno [5, 4 -b] furan -8- il) etil] propionamida, cristais de (s) -n- [2- (1, 6, 7, 8 -tetraidro -2h- indeno [5-4-b] furan -8- il) etil] propionamida, composição, processo para a produção de 1, 2 , 6, 7- tetraidro -8h- indeno [5, 4-b] furan -8- ona, uso dos cristais, e, método para a prevenção ou tratamento de distúrbios do sono
BR0308292A (pt) Processo para aperfeiçoar a pureza e o rendimento da sucralose
HUP0202536A2 (hu) A pravasztatin nátrium-sójának kristályai
BR0011403A (pt) Processos para a purificação e para a preparação de ácido acrìlico ou ácido metacrìlico
PE20040767A1 (es) Derivado hemisulfato de azido citosina cristalino anhidro
BR9815862A (pt) Processo para preparação de zeólito l cristalino
BR0317594A (pt) Processo para a preparação de uma forma &#34;i&#34; de olanzapina polimórfica farmaceuticamente pura, produto resultante e processo para remoção da impureza &#34;s&#34; a partir da forma i polimórfica de olanzapina
AR046229A1 (es) Procesos para la preparacion de cefalosporina 3-(2-vinilo sustituido) altamente pura
BR112019002432A2 (pt) cristalização de glicosídeos de esteviol
PE20010151A1 (es) Nuevas formas cristalinas de un antibiotico macrolido
PE20010287A1 (es) Sal difosfato de un derivado de 4&#34;-sustituido-9-desoxo-9a-aza-9a-homoeritromicina y su composicion farmaceutica
DOP2001000175A (es) 5-cloro-3-(4-metasulfonilfenilo)-6´-metil-[2,3´] bipiridinilo en forma cristalina pura y proceso para la síntesis
AR047061A1 (es) Sintesis de un polimorfo de clorhidrato hidratado de 4-amino-5-cloro-2-metoxi-n-(1-azabiciclo[3.3.1]non-4-il)benzamida
MXPA01000559A (es) Nuevos derivados de la 6-desoxi eritromicina, su procedimiento de preparacion y su aplicacion como medicamentos.
UY24241A1 (es) Procedimiento de preparación de nuevos polimorfos de diclorhidrato de lesopitron.-
CU23698B7 (es) Procedimiento de preparación de la forma cristalina delta d del clorhidrato de ivabradina y las composiciones farmacéuticas que las contienen
GB1158396A (en) New Spiramycin Derivative
JPS62178597A (ja) １，２，５−トリ−ｏ−アセチル−ｄ−グルコフラヌロノ−６，３−ラクトンのアノマ−の分離法

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.